RHAMM drives formation of polyploid cancer cells and confers resistance to ER-targeted therapy in breast cancer
Proceedings of the National Academy of Sciences · 2026
DOI: 10.1073/pnas.2535342123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Shiyi Wu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, …. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Resistance, Neoplasm, Polyploidy, Receptors, Estrogen. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
Endocrine resistance in ER + breast cancer remains a major clinical challenge. Here, we identify RHAMM as a key driver of resistance by orchestrating polyploid cancer cell (PCC) formation. Single-cell transcriptomics uncovered a G2/M-enriched, RHAMM + subpopulation in endocrine-resistant tumors. Mechanistically, RHAMM binds Septin9/10 to promote aberrant cytoskeleton polymerization, activating YAP independent of Hippo signaling, which induces cytokinesis failure and facilitates PCC generation. Concurrently, RHAMM destabilizes p21 mRNA, enabling cell cycle progression despite genomic instability. The RHAMM–p21 axis serves as a bypass mechanism supporting polyploidization. Upon endocrine treatment, RHAMM is transcriptionally up-regulated by Slug. Clinically, RHAMM high signatures are enriched in metastatic and recurrent ER + tumors and correlate with poor prognosis, highlighting its therapeutic relevance. Importantly, targeting RHAMM or YAP abrogates PCC formation and restores fulvestrant sensitivity. These findings reveal RHAMM-mediated polyploidization as an adaptive mechanism underlying endocrine resistance, suggesting the therapeutic potential of targeting the RHAMM–YAP axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
- Department of Molecular Biology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
- Faculty of Medical Laboratory Science, College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- Department of Breast Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
- Department of Pain Management, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
ORCID-Profile: Bohan Liu, Fen Tang, Cuixia Yang
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
Zitieren
APA
Wu, S., Chen, S., Liu, B., Liu, Y., Yang, S., Hu, J., He, Y., Liu, Q., Liu, Y., Du, Y., Zhang, G., Guo, Q., Gao, F., Tang, F., Xu, Y., & Yang, C. (2026). RHAMM drives formation of polyploid cancer cells and confers resistance to ER-targeted therapy in breast cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2535342123
Vancouver
Wu S, Chen S, Liu B, Liu Y, Yang S, Hu J, et al. RHAMM drives formation of polyploid cancer cells and confers resistance to ER-targeted therapy in breast cancer. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2535342123
BibTeX
@article{Wu2026,
author = {Wu, Shiyi and Chen, Si and Liu, Bohan and Liu, Yuting and Yang, Siyue and Hu, Jiajie and He, Yiqing and Liu, Qinqing and Liu, Yiwen and Du, Yan and Zhang, Guoliang and Guo, Qian and Gao, Feng and Tang, Fen and Xu, Yongming and Yang, Cuixia},
title = {RHAMM drives formation of polyploid cancer cells and confers resistance to ER-targeted therapy in breast cancer},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
doi = {10.1073/pnas.2535342123}
}
EUVIMED